Recent filings reveal significant shifts in institutional investment within Cigna Group (NYSE:CI), with major players adjusting their positions in the prominent health services provider. These movements underscore the dynamic nature of large-cap stock holdings and reflect evolving investor strategies amidst market conditions.

One notable development emerged from US Bancorp DE, which reportedly trimmed its stake in Cigna Group during the first quarter. According to its latest Form 13F filing with the SEC, the firm reduced its holdings by 4.0%, offloading 4,287 shares. Despite this reduction, US Bancorp DE retained a substantial portfolio of 102,366 shares, valued at $33,679,000 as of its most recent disclosure.

Conversely, other institutional investors have significantly increased their exposure to Cigna. T. Rowe Price Investment Management Inc. made a substantial entry, acquiring a new stake worth $724,517,000 in the fourth quarter. This highlights a strong conviction from some large-scale asset managers regarding Cigna’s long-term prospects.

GAMMA Investing LLC demonstrated an exceptionally bullish stance, dramatically growing its position in Cigna Group by an astounding 58,799.0% during the first quarter. This massive acquisition resulted in GAMMA Investing LLC holding 1,774,626 shares, valued at $583,852,000, signifying a significant belief in the Cigna Group stock trajectory. Similarly, Two Sigma Advisers LP boosted its holdings by 278.0%, now owning 816,200 shares worth $225,385,000.

Further reinforcing the trend of increased institutional confidence, Voloridge Investment Management LLC expanded its Cigna holdings by 400.9%, accumulating 643,253 shares valued at $177,628,000. TAM Capital Management Inc. also initiated a new position, valued at approximately $128,590,000, collectively leading to a remarkable 86.99% of Cigna stock being owned by institutional investors and hedge funds, a clear indicator of its strong appeal in healthcare investments.

On the trading front, Cigna Group shares recently opened at $262.26. The company has experienced a twelve-month trading range between a low of $256.89 and a high of $370.83, illustrating market volatility. Key financial metrics show a current ratio of 0.71, a quick ratio of 0.72, and a debt-to-equity ratio of 0.65, along with a market capitalization of $70.06 billion, reflecting its solid financial standing and the continuous analysis of CI stock performance.

The company’s stock has maintained a 50-day moving average of $308.90 and a 200-day moving average of $312.11, indicating steady performance. Furthermore, Cigna boasts a price-to-earnings ratio of 14.32, a price-to-earnings-growth ratio of 0.79, and a beta of 0.47, metrics crucial for share performance analysis and investor evaluations.

Adding to its appeal, Cigna Group recently declared a quarterly dividend of $1.51 per share, payable on September 18th, with an ex-dividend date of September 4th. This translates to a $6.04 annualized dividend, offering a dividend yield of 2.3% and a payout ratio of 33.44%, vital information for dividend analysis for current and prospective shareholders.

Equity analysts have largely maintained a positive outlook on Cigna Group, with firms like Truist Financial, Guggenheim, Morgan Stanley, and Barclays reaffirming or increasing their price targets and “buy” or “overweight” ratings. While Robert W. Baird adjusted its target slightly, the overall consensus from MarketBeat.com data shows an average rating of “Moderate Buy” and an average price target of $378.67, highlighting strong confidence in its institutional ownership and future growth.